Literature DB >> 1580793

Chromium (VI) reducing capacity of ascorbic acid and of human plasma in vitro.

M Capellmann1, H M Bolt.   

Abstract

In the metabolism of chromium(VI) its reduction in human plasma is of importance; an extracellular reduction of Cr(VI) is regarded as a detoxification step. Ascorbic acid has been suggested to represent the majority of the Cr(VI)-reducing capacity of human plasma. Therefore the kinetics of the reaction of Cr(VI) with ascorbic acid, at biologically realistic concentrations were studied. Ascorbic acid, in 0.2 M HEPES buffer and at concentrations ranging from 14.2 to 113.6 nmol ml-1 (2.5-20.0 microgram ml-1), was mixed with Cr(VI) (0.4-1.5 nmol ml-1) and incubated at pH 7.4 and 37 degrees C. In addition, chromate solutions at different concentrations [1.5-100 nmol ml-1 Cr(VI)], were incubated at 37 degrees C with freshly drawn blood. From these incubates, ascorbic acid and its oxidized form, dehydroascorbic acid, were simultaneously analyzed by HPLC and post-column derivatization. Chromate was determined by flow injection analysis. The reaction kinetics of ascorbic acid in HEPES buffer with Cr(VI) is of pseudo-first order at higher concentrations, whilst apparently at lower concentrations kinetics are consistent with an autocatalyzed reaction. Results obtained after spiking human plasma are similar. However, when Cr(VI) was reacted with human plasma, no changes in the intrinsic contents of ascorbic acid of the plasma samples occurred. Also, comparing different plasma samples the intrinsic plasma contents of ascorbic acid and the reduction capacities for Cr(VI) [ranging between 0.48 and 0.63 nmol ml-1 Cr(VI) to be reduced] did not correlate. This shows that the reduction of Cr(VI) in native human plasma is complex and is not only determined by the plasma ascorbic acid levels. This is in contrast to the situation in lung lavage fluids (Suzuki 1988; Suzuki and Fukuda 1990) where the concentrations of ascorbic acid are much higher than in blood.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1580793     DOI: 10.1007/bf02307269

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  6 in total

1.  Reduction of hexavalent chromium by ascorbic acid in rat lung lavage fluid.

Authors:  Y Suzuki
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

2.  Activation of chromium(VI) by thiols results in chromium(V) formation, chromium binding to DNA and altered DNA conformation.

Authors:  K M Borges; J S Boswell; R H Liebross; K E Wetterhahn
Journal:  Carcinogenesis       Date:  1991-04       Impact factor: 4.944

3.  Mechanisms of chromium toxicity in mitochondria.

Authors:  D Ryberg; J Alexander
Journal:  Chem Biol Interact       Date:  1990       Impact factor: 5.192

4.  Chromium bond detection in isolated erythrocytes: a new principle of biological monitoring of exposure to hexavalent chromium.

Authors:  J Lewalter; U Korallus; C Harzdorf; H Weidemann
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

5.  Ascorbic and dehydroascorbic acids simultaneously quantified in biological fluids by liquid chromatography with fluorescence detection, and comparison with a colorimetric assay.

Authors:  A Lopez-Anaya; M Mayersohn
Journal:  Clin Chem       Date:  1987-10       Impact factor: 8.327

6.  Reduction of hexavalent chromium by ascorbic acid and glutathione with special reference to the rat lung.

Authors:  Y Suzuki; K Fukuda
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

  6 in total
  3 in total

Review 1.  Role of cellular antioxidants in metal-induced damage.

Authors:  M Sugiyama
Journal:  Cell Biol Toxicol       Date:  1994-02       Impact factor: 6.691

2.  The role of glutathione in the acute nephrotoxicity of sodium dichromate.

Authors:  K J Na; S Y Jeong; C H Lim
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

3.  Use of molecular epidemiological techniques in a pilot study on workers exposed to chromium.

Authors:  M Gao; L S Levy; S P Faux; T C Aw; R A Braithwaite; S S Brown
Journal:  Occup Environ Med       Date:  1994-10       Impact factor: 4.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.